Colorectal Cancer | Access and Reimbursement | Optimal Sequencing of Angiogenesis and EGFR Inhibitors in Colorectal Cancer | US | 2016

Seven premium-priced therapies—Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza—are approved in the United States for metastatic colorectal cancer. Therefore, medical oncologists have numerous treatment options for their metastatic colorectal cancer patients, and are looking to optimize the sequencing of these therapies in a way that will lead to the maximal outcome for patients and make the most efficient use of available funds.

Login to access report

launch Related Market Assessment Reports